Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma

Vijaya R. Bhatt, Smith Giri, Vivek Verma, Sumit Dahal, Binay K. Shah, Ranjan Pathak, R. Gregory Bociek, Julie M. Vose, James O. Armitage

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Background: This large population-based study determined the epidemiology and outcomes of secondary acute myeloid leukemia (sAML) developing in Hodgkin lymphoma survivors. Methods: We utilized the Surveillance Epidemiology and End Results (SEER) 9 database to identify 104 cases of sAML. Results: Patients with sAML (median age: 47 years; 82% <60 years) were significantly younger than de novo AML cases (66 years; p < 0.01). sAML had worse overall survival (OS) than de novo AML (p < 0.01). OS was better in younger patients and in more recent years. Conclusion: Older patients with sAML have a dismal OS and should be enrolled in trials of novel therapies. Younger patients have improved OS and hence may benefit from curative intent intensive therapy and allogeneic transplant.

Original languageEnglish (US)
Pages (from-to)1565-1575
Number of pages11
JournalFuture Oncology
Issue number13
StatePublished - Jul 2016


  • Hodgkin lymphoma
  • acute myeloid leukemia
  • survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this